particularly pharma which may have the best pipeline in the industry. consider when he took over in 2012 he had to clean up a mess at the consumer business. under the leadership of his predesessor, the fda sanctioned johnson & johnson not once but repeatedly in the over-the-counter drug business forcing him to recall more than 135 million bottles of tylenol and other over-the-counter drugs. as a result of the recall jnj signed an agreement with the fda that put three plants under tight regulatory scrutiny and shut down the huge facility in fort washington, pennsylvania. all together jnj over-the-counter sales declined in 2009 to 2012. gorsky fixed the problems and the fda allowed them to restart production at fort washington in where i grew up. this business includes motrin, sudafed and other products. they were sanctioned so heavily and repeatedly by the fda. in terms of their problems that was the tip of the iceberg. j&j has a hepatitis c franchise that's just been crushed by koch technician from gilead that cures he p-c. sales fell last year. fell be

so it's the same in pharma. it's interesting when she's calling out this industry, saying they are her enemy, they still are giving her the most money. >> this is emblematic for what is wrong with washington. this is why the fringe candidates are getting what they're getting, because they seem to be unaffiliated with anybody. i'm sure hillary has taken an enormous amount of money, even from the nra. think about where washington and corporate america are conflicted, lobby groups. this is the biggest problem. unfortunately, that's not a reason to vote for someone who has no affiliation. >> this is more synonymous with the banks. i'm sure she's got the most money from the banks, too. they found biotech is the new banks as far as donations, as far as the new target zone. and that's what's going on right now. >> i think mike brings up a good point in knowing what you're dealing with. as far as proposals, you know better what -- at least you can deal with it. the market doesn't like uncertainty. at least you're certai

does big pharma have that much clout or too much clout?> big pharma certainly has a lot of cloud and there's a whole regular layatory system they function in and drugs in the united states are higher than anywhere else in the world but there's a ton of innovation that they do and research that they do and they argue that those drugs don't come from nowhere, but certainly, they as a very large industry do have a lot of influence in both the way they're regulated and in marketing the products that they put out. >> let me go back to that $3.5 billion figure. is that shatters trust between doctors and patients, because we trust that our doctor is telling us to take a pill because it might make us better, but are you concerned this some doctors are pushing pills because big pharma is pushing their buttons? >> i think there were some very interesting and powerful findings in the study that you mentioned. one was that a significant significant percentage of doctors reported no contact with pharma and there was no financial exchange between them a

the headwinds to pharma with both major candidates being -- finding pharma to be one of the guilty partiesakes it difficult. i would say people feel ackman is in it for the long-term. he was always in it for the long-term. he had his guy on the board. if he joins the board, that says there's no insider selling. meaning there's no ackman selling, even though ackman was not -- >> could sell mondelez instead. >> yes. mondelez holds up well. i don't know. valeant is going up because i think people feel there's a grown-up in charge again. i would like to see someone from the outside. a real grown-up. a bill george. a great cnbc contributor. he could come in and be a monitor by the governor. if you saw fred hasen's name, you take it to 35. he would refinance that debt quickly. >> value x was asked about pearson last week. here's what was said about pearson at time. >> he is incredibly driven. incredibly smart. he's a great problem solver. we're solving problems as we think. we think mike is the right guy for the job. >> he's incredibly gone, too. he left -- that's the benefit of hindsight. this

i think there is enough quality pharma to reach down the food chain for something like valeant. i think it's worth noting something else that suggests stocks are under value. from giant oil bellwethers. transocean, a rig company and schlumberger, about how it could be years before things get better in the oil patch. i couldn't imagine a better reason to take profits in the oil and gas stocks than these two companies seeing siren songs for the near term. the stock's barely budged. some went higher. ones downgrade. that's called resilience. and tech. we've been devoid of tech news lately but the group keeps climbing. the pre-february bottom days, the choice of direction was down, now seems higher. what's the significance? once again when you have groups that rally on no news, that is a sign of money flowing in and belief the world is getting stronger, not weaker. hey haven't had nasty news out of china. we had bullish figures from europe last night. apple, so important to the complex rallied on what many said was a nonevent of a meeting smaller phone which judging by the reaction

. >> reporter: -- reaction to news that a pharmaceutical company called gw pharma was able to reduce convulsive seizures in children with the help of a marijuana-based drug was quick and, dare we say, very high. >> it's very positive overall. the thing that jumps out to us is the recognition by the federal government about the efficacy of these drugs. >> reporter: while investors doubled gw stock in one day and saw shares of another marijuana pharma company zynerba rise 150% some doctors say we're likely getting ahead of ourselves. >> it's totally too early to put care in that sentence. >> reporter: and that much more work is needed before we're even close to actual fda approval. >> i think there's a strong emotion in the medical marijuana community that we're going to find some use for marijuana, but it's much more complicated than that. >> reporter: too early to call it a milestone perhaps, but a day that at least sparked new interest in medicinal pot. and should the drug in question become some day fda approved, it would be the first prescription drug extracted from marijuana. rep

i think there are a number of capable ceos who have been at large pharma or specialty pharma companiesrested. >> we have to go. david thank you very much. >>> when we return, jim cramer will join us. more on valeant and on biotech and what's on jim's minds coming up. hey, jesse. who are you? i'm vern, the orange money retirement rabbit from voya. orange money represents the money you put away for retirement. over time, your money could multiply. hello, all of you. get organized at voya.com. >>> welcome back, everyone. let's get down to the nyse. jim cramer standing by. jim, i'm trying to hear your take on what people should be doing ahead of the fed. it seems like investors have been frozen the past couple of days waiting to hear a decision before making any big bets. >> it's hard to say. when they say business isn't that strong, there are guys who want to tighten. we'll focus on the guys who want to tighten. if they say we're going to go with june or even april as steven said, it's hard to believe why the stock would go up. the financials should go down because they've been hanging in

another biotech company is also pharma is news, gw trading back toward its highs.ail, thank you so much. sean parker was largely linked to the rise of piracy and the collapse of the music industry. he explains why he thinks the music industry has turned a corner. sean: consumers turn to piracy by and large they cannot get the product through legitimate channels, so there needed to be a legitimate market offering coming from the record labels, and they could not get their act together for years to put that in the market. it was frustrating to watch this long deleterious collapse of an industry that was producing something that i loved so much. that was never our intention. >> music sales peaked in 1999 and since then, it has been years of decline. you are now on the board of spotify. do you think streaming services can end the years of decline the music industry has been facing? sean: i think we have turned the corner and are getting back into growth based on what i've seen at spotify and apple. it looks like it has bottomed for a wild, of -- spotify could replace c

had they done that, had they told purdue pharma that you can't market the drug to the be authorities then we wouldn't have the trouble today. >> they had the authority to can that did they not? >> if they were appropriately enforcing federal law that's exactly what they would have done. in part they were swayed by the same campaign that was swaying the rest of the medical community but also there has been a very cozy relationship between the reergt regulators ae fda and the same official who approved oxycontin ended up working for company that made oxycontin. >> did this happen? >> yes, it did. >> addiction specialists at the veterans administration know that patients can be addicted to medications that they get there and some have begun pushing for a new tool to stop overdose deaths. al jazeera's jake waral jazeera. >> this veteran says he has been addicted to heroin and prescription opioids for most of his life. and for boston like so many veterans heroin and prescription opiates offer the same risk of death from overdose. that's where the be veterans administration has a massive p

first, there's big pharma. in the mid-1990's, the seeds of the epidemic were plangtsed with the -- planted with the aggressive marketing of the powerful opioid painkiller objectioisthere objectioncy cony purdue pharma. they claimed that it was not addictive and couldn't be abused of the neither of those claims turngdz out to be true. purdue inarm ma built a massive marketing and sales program from 1996 to 2000, purdue pharma's sales force doubled to almost 700,000 sales representatives. in 2001 alone, they gave out $4r0 million in bonuses to its burgeoning sales force. as a result of these sales and marketing effortsings from 1997 to 2002, oxycontin prescriptions increased almost tenfold from $670,000 in 1997 to $6.2 million in 2002. but purdue's marketing of oxycontin broke the law. in 2007 purdue pharma paid $600 million in fines and other payments after pleading guilty in federal court to misleading regulators, doctors, and patients about the risks of addiction to oxycontin and its potential for abuse. secon

specialty pharma higher.saw some of these stocks rallying yesterday, asked americater bank of merrill lynch dropping them. today,hree stocks rally leading a broad rally in pharma biotech good finally, -- biotech. finally, drilling. to risey not be able for three years. highlighting some individual movers on a day when stocks overall are not much changed. david: thanks very much. what explains it? i talked? with some of our colleagues in london today. processing this attack, but not huge dips. we are seeingat is people getting used to this sort of thing. we see headlines like this with increasing frequency. investors also have a lot of other attributes to look at, especially here in the u.s., with robust earnings growth and a little bit of editing of years of fears in a slowdown of global growth. a headline like that will be negative in the short-term, but as people digest some of the other information in the market, they decided the market would be little changed. and we are getting help from two of the most

the real page just says city of pharma pd. >>> odot official recess hosting a meeting today inviting the public to discuss changes along route 18 in medina. widening project is planned to improve traffic safety and reduce congestion. >>> also happening this evening browns coach jackson will be stopping by the cleveland auto show. he'll be there to sign auto graphs and chat with fans from 6:30 to 8:00 tonight. the auto show runs through sunday. >>> still ahead the officer who arrested sandra bland is out of a job and he'll be facing some serious charges but they're not directly related to her death. >> also americans weighing in on the supreme court nomination process, find out how many want the decision to fall to the next president or this president. we'll have the story upcoming. >> and a chance to have all your ohio primary questions answered, all of that is ahead. this is >>> what is termed the republican party establishment is in a battle to stop what was once considered unthinkable, a donald trump general election ticket. there's a panic in the party and it has brought out past

sean: i think pharma has done a oflly poor job drugstanding where past safehave been demonstrated inse one and phase two clinical trials could have been approved in a much narrower indication. it may mean that you need access to a drug the only 300 people other people need access to. we don't have a regulatory framework today that is very good at getting drugs to market. emily: what is next for sean parker? sean: i think life sciences is the single most interesting area of expiration. it is what social media was to meet in 2002-2004. is easy for a grad student to do something that someone would have spent 30 years of their life to do previously. i think cost reduction, because of new technology, leading to faster and faster progress, are an enormous opportunity. i think the question for this waiver century is how do we make sure that the technological innovations coming out of life sciences are available to everyone. emily: sean parker, think you so much for joining us today on studio 1.0. thank you for having us at your fabulous house. sean: thank you. ♪ haslinda: hello, and welcome

yet you talk to pharma people privately, they were afraid to criticize it.ust like talking to telecon people. we used to talk about bernie ebbers and world come, they were trying to figure out at&t how do they do it? well, because the model is a flawed model, not fraud. >> flawed, but i suspect fraud here. that filla door specialty business is bizarre. it's why specialty pharma kpriss doesn't make sense the way we are distributing some of these drugs. >> gentlemen, thank you. >>> to dominic chu. >> small cap stocks, the russell 2000 tracking for its worst performance in week. many of the biggest laggers are biotechnology names. all down double digits. you can see there. the index is still off by more than 17% from its june intraday high. small caps, melissa, remember we had been seeing outperformance that gave the bulls fuel. now small caps turning lower. >>> straight ahead on our new series make it, how one entrepreneurs is pumping profits out of an abandoned prison. we'll be right back. when you're on hold, your business is on hold. that's why comcast busi

. >> a reward he hopes to share with others, but concerned big pharma sees profits, not people. adam may, al jazeera, baltimore. >>> next up here, the worst of two evils. we consider the options for heroin addicts in new hampshire when the only shot at finding a cure is behind bars. >>> and later a surprising legacy. the memorials to love, loss and why survivors want their final words to speak the truth. al jazeera america gives you the total news experience anytime, anywhere. more on every screen. digital, mobile, social. visit aljazeera.com. follow @ajam on twitter. and like aljazeera america on facebook for more stories, more access, more conversations. so you don't just stay on top of the news, go deeper and get more perspectives on every issue. al jazeera america. merica. >>> heroin by the numbers now. use of the drug by young people is more than doubled in the last decade, and overdoses quadrupled. what can save lives? well perhaps facing the truth about drug death. in a striking grassroots movement signs that families want the final legacy of their children, however painf

that gain for shares of gw pharma, doubling today, 129% higher.re going talk to the company's ceo. that's coming up on "power lunch." wow, that was random. random? no. it's all about understanding patterns. like the mail guy at 3:12pm every day or jerry getting dumped every third tuesday. jerry: every third tuesday. we have pattern recognition technology on any chart plus over 300 customizable studies to help you anticipate potential price movement. there's no way to predict that. td ameritrade. woman:man: yes.a newspaper? woman: it's quaint. man: did you read about this latest cyber attack? woman: yeah, i read it on my watch. man: funny. woman: they took out the whole network. man: they had to hand out pens and paper. woman: yeah. man: could it happen to us? woman: no. we're okay. man: we are? woman: yeah, we brought in some new guys. man: what do they know that we don't? woman: that you can't run a country with pens and paper. it's not just security. it's defense. bae systems. >>> the white house saying today it will not rule out new sanctions o

biotech companies revealed to be serial price races, pharma took prices up when they could get away with it. one company valeant built a business model buying other drug companies jacking up drug prices and slashing research and development budgets to make a big profit. i don't necessarily believe in irony as an investing style. yesterday michael pearson, the man behind that valeant business model was fired. with his pending departure, pressure seemed to be lifting from the group. i don't want to pronounce the big bear market over all of health care, however, it does seem to be the case the pressure is off for now with big pharma and fast-growing biotech stocks having reached levels with the sellers seem to have gone away. buyers worried and having a bit of an appetite. even when the market was down off the belgian tragedy this morning, you saw these health care stocks starting to go higher. that was happening because valeant was rallying at the get-go. as investors increasingly seem to think it's over the hump, i worry about the $30 billion in debt valeant has. while you may want to tra

the private equity pharma poll owe will take over the chain for more than $1.3 billion. freshing market is base in greensboro and has nearly 109 stores around the country. >>> it is a southern staple, eat it for breakfast or avel west ofhes e or gri mthionewaearv ter: thiis rks e. the llapbui owe mornday oughounded st c! cornhastt e roth chute. ortethooke it g thh e si si : t just what thneakin youllg down tthe . rter: s.>> canctuay stth at you okg at is e ridge reporr:hat th is ew >> youuy >> rr: jim bar ys ft lled tola whved he30ars ag ani waedcori thg thnde arthpe. >>know whawe ribu reensomeone e shth ere it tathco. beginn rtehehonewly tritiobound.hi. it has gft bn reored. net th ano ey a at jurors re: y yo ew eq it n'ghat tryi tod te ey are ng kea of sty >>br thiss sothheecwi r lyhe raonnera>>or gts oits you sealmost oudi ving seing grs. wave o a e.>> repoer: balemillhaenaking the ppy r sttwo ar ng ithold way hoasan op to d you inise ketoth with usyes. >>reisland, for gera >>wegoi wak wo to grs. eaifryu n tgrit >> hsath asy would d wgrs mi coming bk herehinshmpgritit

with that said, xlv is the etf for the bigger cap pharma. that's getti inting hammered si the beginning of the year. dan gave them some flack -- >> there was a lot in between. >> can we queue that up? >> he said to be careful. now you have biotech trading well below the trading. i don't think anybody will pull the trigger in this environment because there's no up side in doing it. you've got to wait for the smoke to clear and it ain't clearing anytime soon. >> this is a trade i've been on for a while, pfizer. i think it probably goes up at some point with more clarity about the allergen deal one way or another. down 20% from the 52-week high. it trades about 13 times. you don't buy pharma -- i think while you're waiting, you can actually sell against it and add to that yield and hang on to it. to me, i also think guy's right about the xlv. that is the etf. you have all this other stuff, the xpi, a lot more volatile. johnson and johnson, merck, that's where i would go down. >> dan mentioned an option strategy. is there a show that's on that y

sean: i think pharma has done a really poor job of understanding where past drugs that have demonstrated in phase one and phase two clinical trials, you know, could have been approved in a much narrower indication. but it may mean you need access to a drug that only 300 other people need access to. we don't have a regulatory framework that is very good at getting those drugs to market. emily: what is next for sean parker? sean: i think life sciences is the single most interesting area of exploration. it is to the world today what social media was to me in 2002, 2003, 2004. the ability to get to get something where a grad student would spend 30 years of their life trying to do previously. but i do think that cost reduction, because of new technology leading to faster and faster progress, there are enormous opportunities. i think the fundamental question of the 21st century is, how do we make sure that the technological innovations coming out of life sciences are available to everyone? emily: sean parker, thank you so much for joining us on "studio 1.0." thank you so much for having us at

pharma, the purdue list of america's richest families. estimated $14 million. yesterday i was talking to a reporter, he was saying that aren't you concerned that with more money being requested for treatment and to deal with this problem, because there are so many more people getting into opioids and heroin, that money that itspread so thin will not have the impact you are hoping for? >> we need to rein in behavior in the united states. closely follow the guidance that dr. when put out. that is the significant driver. we also know that despite all of our efforts, we still have too many people overdosing in dying. the cousins cannot access treatment programs when they need to make programs. as is why the president has to put forward a significant proposal to expand treatment capacity in the united states. i hear this wherever i go. in toledo,nhall ohio, where the sheriff -- i asked the sheriff one thing the government should be adjusting this opioid epidemic, he did not say we need police officers, he said we need more treatment capacity because we are arresting

the promotion of oxycontin by purdue pharma was the most aggressive marketing of the schedule ii drug ever undertaken by a pharmaceutical company. one family, which owns the stanford connecticut-based purdue pharma, is one of america's wealthiest families. the richest newcomers to the list are worth an estimated $14 billion. $14 billion. as she explains, the united states has 5% of the world's population, but we consume 80% of the world's painkillers. tweet that. 5%, ladies and gentlemen, of the world's population, but 80% of the world's painkillers we consume. so yes, i believe it was unconscionable that the nation ignored this issue for decades, but now republicans and democrats are starting to work together. i thank god that this day has finally come, and the stars are starting to align, for meaningful change. we now have people like orrin hatch, chris christie, rob portman, kelly ayote realizing the severity of this crisis and providing more funding to help our cities and states. they are beginning to realize that this is not an urban issue, april issue, a black issue, an hispanic

>> i think if you're -- there's a rolling bear market that's now in pharma.hat money comes out of pharma, what's left of it. >> when will it come out? the point i made earlier, last year was a terrible year for hedge funds. we all know that. this year, now that we're back to flat on the broader markets, hedge funds are still down without a doubt. and so many of them own so much healthcare. >> they own biotech. >> we talk about valeant. did you see endo? these things trade together. >> or celgene. >> celgene. that's a bear market that has taken a toll. i wonder what the hedge funds will look like this year versus they are down. it's ugly. >> they shorted adobe, sales force, linkedin, how stupid was that, that adobe conference call. a thing of beauty. >> time for some fresh highs on adobe. >> let's not forget what adobe did during that hideous week of tableau software. the stock was flying. santana was -- santana, did you see the numbers for adobe, up 44%, 175 movies from the sundance film festival used. that stock dropped like a stone off tableau. that stock f

i worked for a diversified specialty bio-pharma company in central new jersey. and as part of my career there, i got to travel to 26 coununies and 4 continents. so... good for you. what is s what is this -- it's a good start,

initially the statute applied to covered sentities, health care providers, hospitals, physicians, pharma pharmacyin pharmacyinpharmacy, health plans and health care clearinghouses. there's also a term called business associates that are under the statute. these are folks that help them in their operations. i think the cleanest example of that is a billing company. you may have a small physician office group that deals with 20 different health insurers and keeping up with the billing requirements can be difficult to do. they hire a billing company to do that. then they have to transmit personal health information to the billing company about their patient so they can properly bill it. initially all the statute required was a contract between that hospital or physician's group and the business associates showing how the business associate was going to keep that data private, keep it safe, the protections in place for it. now since 2009, business associates are under the statute themselves. and the government can force against them. and it's a much different ball game for business associate

this is an amish dairy pharma long the 600 block of street road. feed being stored inside of that barn apparently caught fire and ended up destroying much of the structure as you can see. we're told animals inside were safely evacuated and no injuries have been reported. >>> now to the the 2016 presidential primary race, senator ted cruz, is a winner of wyoming's republican primary in, fact he won by a land slide with 66 percent of the vote, and senator marco rubio was declared winner of the republican caucus in washington d.c. meanwhile republican front runner donald trump is spending his time this weekend in double states with upcoming primaries. this evening he held a rally with hi in kansas city and before the event began announcer asked that the crowd not to touch any protesters in the audience. once trump took stage he did in the hold back his criticism of those trying to disrupt his rallies. within 20 minutes, american a dozen demonstrators were escorted out. >>> earlier today during a rally in ohio, trump was startled when a man tried to ru

he invested in a canadian pharma company and they have cut guidance, they have missed their revenue expectationsckman's response, we're going to get a little more involved with this company to protect our investments. $1 billion on paper, that has got to hurt. back to you. >> oh, i would think. geoff cutmore, live from london, thank you. >>> let's get a check on your weather now with nbc meteorologist bill karins. we have to start with illinois. there was this an election there last night, but the weather was so bad. this is unbelievable. bushnell, illinois, where you could hear the sirens. >> yeah, nine reported tornadoes. some of those were big tornados and they were mostly in western illinois as the voting was wrapping up last night. that's what we were afraid of. the storms didn't get to chicago until 11:00 or midnight. we had a lot of large hail reported. golf ball hail, that's a lowering base of the thunderstorm which can at times produce the tornados and it looks like funnel cloud there in the distance. there's some of the large hail we saw yesterday from illinois. so what are with dealin

. >> a reward he hopes to share with others, but concerned big pharma sees profits, not people. adam may, al jazeera, baltimore. >>> next up here, the worst of two evils. we consider the options for heroin addicts in new hampshire when the only shot at finding a cure is behind bars. >>> and later a surprising legacy. the memorials to love, loss and why survivors want their final words to speak the truth. >>> you've heard about the city of baltimore's struggles with heroin. now we look to the northeast where even the farmlands in states like vermont and new hampshire found they, too, have been caught up in the spread of opiate addiction. already one of the most addictive drugs in the world, heroin has become more available, cheap, and pure. the consequences are evident in new hampshire where the state struggles with record numbers of overdoses, even more worrisome, finding treatment has become even more difficult. "america tonight" takes you inside the place that has become new hampshire's unlikely treatment center of last resort. >> what percentage here out in the yard are addic

finally note, if you want to look at the flip side of this, tyler, pharma is having a little tougheronment. so lilly is at a 52 week low. and some big biotech names like regeneron and alexion at lows. >> a news alert. to dominic chu. >> we're talking about pershing square holdings, the publicly run fund entity run by bill ackman. s&p, credit ratings agency, placed pershing square holdings, again, the publicly traded company, they put their bbb rating, currently investment grade, on what they call credit watch negative. they say they have done this largely because of the precipitous decline in the market value of valeant pharmaceuticals which we know is one of the top holdings here. as a result, they say the debt to total assets ratio has increased. we're placing our bbb issue or credit rating on watch negative. they also say that it reflects the funds weak investment performance which resulted in higher leverage. we heard earlier they don't use, bill ackman in this particular unit, doesn't use margin type investing or margin type tools here. an interesting move here, credit ratings a

this is an amish dairy pharma long the 600 block of street road. feed being stored inside that barn apparently caught fire and ended up destroying much of the structure as you can see. we're told all of the animals inside were safely evacuated and no injuries were reported. >>> a community in south jersey gathered today in support of fallen state trooper sean cullen. line stretched from the front of the shop rite in cinnaminson all the way out the door. these folks are buying blue bows and ribbons to raise money for trooper cullen's family. this campaign dubbed operation blue ribbon started on facebook and simply took off, from there. >> we are seeing people that are helping to buy, pitching in $5 a bow, and they are making their own bow we don't have people to make the bows. the so we're just teaching them as they are standing there in line waiting so they can get the their bow toss she support for the cullen family. >> how about that. so far thousands of dollars have been raised with more events still in the planning stage. >>> meanwhile, a publi

so where do the candidates stand when it comes to pharma?uses right now with a political beat check. >> really the democrats seem to be focusing on this a lot more. if you look at the way they lay out their plans, hillary clinton and bernie sanders have detailed plans for how they want to take on pharma and have made this a big part of their -- >> because they think drug prices have been too high and have been using this as part of the -- >> right, the price-gouging idea. so hillary clinton really focuses on direct-to-consumer advertising. she hates those tv ads you see for lipitor and viagra, and things like that, and she wants to accelerate competition. allow us to import drugs from other countries where they're cheaper. and the biggest up wi egest one medicare to negotiate drug prices. right now we're not allowed to do that. a lot of people argue that would bring down the cost of drugs. there's a lot of argument about how that would work. >> wasn't that part of the deal with the affordable care act, that medicare would not be negotiating?

.>> s sph: wn k souou ar tn tyo h co sphenikow pharma on mainreet? >> yeah,ettingicorice whips? stephen: do you like hingngng kids? >> sometim i i tnk may like it more thanhe kids and when t season is over i get ki of b bmed out. but it's so much fun. i get really excited whe kids >> stephen: yeah. sometimes you're like -- i coached little league soccer for a while a getting theids to pay y tention to where the ball was ononhe field. >> it's the best. >> stephen: we would put 20 balls onhe field,here would so many ballsoun't y4entioto a onef them i so lk at t joy thes e hang youo, iant atld joy >>no 's kd of h hdd to rture th. teph::h. dodiou ling andult? (laughtetete >> uh. io. mea it' i and evhibu's ao ---- a ses kof ag. >>>>teenyeyezeze en a kid, i didn' i dn't know mh, but the fact atathe world was so unknownwn de it kind can of a e eiting mystery, you k kw. >>>>eah,h,ea , ,ouu know -- no, it's true, buthen you grow u and it's, like, you f fd out that driving isn't thatun, and tha you kn, that sex isn'teal, it's just a story they tell you to >>tephen: yeapooky ststf. >> yeah

gw pharma has doubled a $2 billion market cap on the companies key marijuana drug, met a primary endpointate stage study. a biotech company apparently has a similar marijuana drug, gwding up, soaring more than at this point on the close. so much,hank you abigail doolittle at the nasdaq. speaking of tech stocks, they have rallied by the end of the year. more importantly, volatility remains high in the tech sector. -- wegs made colleagues asked him what was behind it all. is across volatility all these investments, really juvenile by the fact you have about 100 companies trading at astronomical valuations. the remaining are not at those high valuations. what something like a linkedin or tableau has it happened, varitek reports across everywhere. >> how many stocks are waiting to reach regular levels? i don't know when they will reach regular levels. most of the market is not that valued on the tech side. >> as an investor, you see this volatility in the tech side. opportunity?at how do you get the best of the theatility and leave rest behind? them of the only way we invest is by a three tim

>> pharma has done a really poor where pastrstanding drugs that have been demonstrated safe in phasese two clinical trials could have been approved in a much narrower indication. but it may mean that you need access to a drug that only 300 other people need access to. we do not have a regulatory framework today that is good at getting those drugs to market. emily: what is next for sean parker? life sciences is the single most interesting area of reflection. to labhe ability to get on ship in so many cases where it is easy for a grad student to do something that someone would have spent 30 years of their life doing previously. i think that cost reductions -- because of new technology leading to faster and faster progress, the fundamental question of the 21st century is, how do we make sure that the technological novation's coming out of life sciences are available to everyone? emily: sean parker, facebook cofounding president, napster founding president, and founder of the parker foundation. it is time now to find out who is having the best day ever. the first place winner of the worl

i also have to talk about what is happening in the pharma world, especially with what is happening with valued we can see a little bit of knock on effect happening here. down by 10.5%, no surprise it is getting hit in tandem with valeant. this is the s&p i's biggest liger today. -- a laggard today. basically, there is a limited growth driver for distributors and they are seeing the end of a 15 year super cycle of generic introductions that are coming to an end. david: oil prices cannot be hoping that. ramy: of course, continually being an issue. energy looking at oil. oil down off session lows by a little more than 2%. this is its first time in a month that we are seeing back-to-back falls, in particular because of a wrong that we have been talking about throughout the day today and yesterday, saying that it will not freeze oil production. and iranian production climbed last month by the most in almost two decades. david: thank you. now let's check on the bloomberg first word news, mark crumpton has more from our news desk. mark: president obama has reversed course on drilling for oil o

have only increased across the pharma industry.from this month owners of eu trademarks to prevent the transit shipment of goods and medicines without authorization. india may challenge the stricter trademark rules that could stop exports of generic drugs. they want them to remove the though shipments, even the eu has signaled that imports of medicine won't be affected. rishaad: thank you. battle of the latest man versus machine, and a victory for artificial intelligence. googles program beat the world's top player in the ancient board game go. it was created by google's deep mind the vision. match was, this streamed. it got more than 1.3 million viewers. the next game is coming up soon. they will be showing all those on youtube. deep mind is an artificial intelligent system. google is a that leader in the next generation of supersmart computing. let's take a look at what the deep mind founder said. we landed it on the moon. , also interested in artificial intelligence, congratulations. we thought they were 10 years away from achiev

let's move to another sector -- the pharma sector.ver at valeant pharmaceuticals, you can see that after his fall from earlier this week that we saw on the order of 50% after the earnings came out, today we are down a little more -- down by more than 8%. we are looking at the stock at its lowest since december, 2010. what is happening today is always weighing them down. valeant started talking to lenders asking them what they would want to give valeant in order for valeant to get for given on some of its debt, and that is because of the delayed earnings announced earlier this week. for the entire week, valeant is down on the order of 60%. speaking in health care -- let's look at what the health care sector is doing. generally, looking at tenant, community, and hca, on the order of 6.5%, and the sector is actually up by 1.3%. the biggest and best performer right now. this is off the back of what is happening in new jersey. new jersey governor chris christie came out to protect hospitals from losses, saying he on wants a two-year ban la

a jury awarded the owner of the pharma company to pay $200 million to merk because of a patent case involving hepatitis b. interestingly, mark was wanting to billions wanting dollars. billion. it will be interesting looking i had to thursday when she makes a speech -- looking ahead to thursday when she makes a speech and maybe gives us some guidance there. cory: oculus rift is finally hitting the market today. is it good enough? ♪ cory: tokyo, we have a problem. they're launching a brand-new satellite. it was equipped with x-ray telescopes meant to study black holes. lost contact saturday afternoon and have been trying to reconnect ever since. some suggest that an energetic event may have sent it tumbling out of control and prevented the antenna from working properly. officiallyrift has hit the market two years after facebook surprised -- facebook's surprise to billion dollar acquisition -- 2 billion-dollar $2 billion dollar acquisition. era ofll this the new virtual reality. something that some give credit to mark zuckerberg for sparking. >> when the ceo of a multibillion dollar company gets

less than seven mondays, part of that weekness had to do with the whole biotech industry and the pharma especially after hillary clinton declared her crusade against high prices. last november incyte rolled out results from the phase 2 trial of a drug designed to prevent the growth of many kinds of tumors. the stock got slammed because the drug demonstrated a lower response rate. highly unusual. it took incyte from 115 down to 100. the stock held there for a few months, but then got obliterated on no real negative news, simply because the rest of the market was selling off the biotechs, but the final blow in january alongside strong quarterly results, it announced it was discontinuing the phase 3 trial of this pancreatic cancer drug. i was shocked. i thought this one was in the bag. i'm not kidding. i thought -- it shocked everybody. the stock settled at $65 even as analysts caused the sell-off overdone. since then it's bounced back and roared today on positive data with the arthritis drug. but if you own incyte through this whole period, you're still hurting. what are the lessons? firs

the sackler family, which owns stamford, connecticut-based purdue pharma, achieved a place on forbes'015 list of america's wealthiest families. the sacklers, the richest newcomers to the list, are worth an estimated $14 billion. $14 billion. now, going on, so as she explains, the united states has only a 5% -- in this article, we have 5% of the world's population, but we consume 80% of the world's painkillers. tweet that. 5%, ladies and gentlemen, of the world's population, but 80% of the painkillers we consume. so, yes, i believe it was unconscionable that our nation ignored this issue for decades, but now republicans and democrats are starting to work together. and i thank god that this day has finally come, and the stars are starting to align for meaningful change. we now have people like orrin hatch, chris christie, rob portman, kelly ayotte and mike pence realizing the gravity of this crisis and supporting more funding to help our cities and states. they're beginning to realize that this is not an urban issue, a rural issue, a black issue, a hispanic issue, or a white issue. this

within pharmaceuticals, some of the best-performing stocks if you look at the large cap pharma, you havellergan, amgen, and pfizer all on the rise of this point. the drastic by index is having a big day as well. a specialty pharmaceutical big cap pharmaceutical, but also biotech higher up by 2.5% right now. that's a big part of the game we're seeing today. again, complete with divorced, really, from what we are seeing happen in europe today. matt: interesting stuff, julie will keep covering the markets. we will check on the first word news with mark crumpton. mark: the latest on today's attacks in brussels, which have left 31 people dead and another 230 injured. islamic state is claiming response ability for the violence. a total of three explosions rocked the city, including two over the brussels airport which will be closed at least through wednesday. another blast included a downtown subway station. world leaders have condemned the violence. belgium's prime minister has declared three days of national mourning. president obama says he is in cuba to bury the last remnant of the cold wa

oneme saw d sasa it wh oil companies sitting on huge gas ge gasasososngs and d d e thth bids frobig pharma companies or approvals sf new drugs. these specululioio oeno however haha t f life cle of a y fly.y. the trtrk isiwirst alwlws remember to lock in your profits whenenou he thememem@m don't get burned ghen interest -- wheinterest wanes. cut some of it dn. second, second, your losses, those you have to cut before they b come too larg w wn spececou thought sn't panning out, just leave it. when y s sculala you're not tryingngo nd a s sck you can y and forer....yu want s sething goingighe ananring theheegister,oe't mattf c b bla dot do thawiwi stocks with bad or deteriorating fuentals, that's stud specul weaid weike timemex an biotech forltrades when we did them on speculation fridays. when lightningtruck,k,e said, take all the gains please. eyencrated never lked back. you said jim, you said you loved it. loved it for trades. you need diversification that will potentially allow you to o rack up huge gains. lots of fantastic stocks started at speculations and just because 's bucks doesn't m

the family which owns purdue pharma, achieved the list of america's wealthiest families. the richest newcomers to the list are worth an estimated $14 billion. that's appalling. i call that blood money because people are dying. i want to go back to something, ms. enomoto. yesterday i was talking to a reporter. and he was saying that, cummings, aren't you concerned that with even more money being requested for treatment and to deal with this problem, because there are so many more equal getting into opioids and heroin, that money will be spread so thin that it will not have the kind of impact that you're hoping for. >> sure. to your point, i think we have to have a comprehensive response. and first and foremost, we need to rein in prescribing behavior in the united states. the centers for disease control just put out recommendations last week that closely follow the guidance that dr. wen put out. that is where we know is the significant prerogative. but we also know that despite all of our efforts, we still have too many people overdosing and dying, largely because they can

why are so many americans taking on that yes, i dos and isn't big pharma mostly to blame? isn't anything going after the pharmaceuticals. >> there's been a lot of critique of the pharmaceutical cross and marketing of pain medications. over the past 20 years we've seen a significant push to provide pain pills that are often very powerful and have their own risks to a broader and broader group of patients. twenty years ago, they were reserved for end of life care and cancer treatment and now used for headaches, lower back pain, other conditions that could be better treated through other means. >> isn't this creating what some would say would be a perfect crime if big pharma is to blame for pushing these opioid in the first place, now they're going to make billions which dollars off of the solution for drugs like narcan. >> i'd loves to that we are spending billions of dollars on narcan to prevent opioid deaths, but we're spending $2 billion a year on pain killers. i don't think it's going to be easy to get out of this problem, but i do think that there's a role for medicatio